Towards efficient cancer immunotherapy: advances in developing artificial antigen-presenting cells

Highlights • Active immunotherapy is promising for the development of potent cancer therapeutics. • Various types of artificial antigen-presenting cells (aAPCs) may be used as ‘off-the-shelf’ products to induce antigen-specific T cell activation both ex vivo and in vivo. • Size, shape, cytokine deli...

Full description

Saved in:
Bibliographic Details
Published in:Trends in biotechnology (Regular ed.) 2014-09, Vol.32 (9), p.456-465
Main Authors: Eggermont, Loek J, Paulis, Leonie E, Tel, Jurjen, Figdor, Carl G
Format: Article
Language:English
Subjects:
Antigen-Presenting Cells - physiology
Antigens
artificial antigen-presenting cell
Artificial Cells - immunology
Biomedical Research - trends
cancer
Humans
Immune system
Immunotherapy
Immunotherapy - methods
Internal Medicine
Lymphocyte Activation
Neoplasms - therapy
Review
synthetic dendritic cell
T cell receptors
T-Lymphocytes, Cytotoxic - immunology
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Highlights • Active immunotherapy is promising for the development of potent cancer therapeutics. • Various types of artificial antigen-presenting cells (aAPCs) may be used as ‘off-the-shelf’ products to induce antigen-specific T cell activation both ex vivo and in vivo. • Size, shape, cytokine delivery mechanism, ligand composition, ligand mobility, and ligand positioning on aAPCs all have significant effects on T cell activation, and therefore should be taken into account when designing novel constructs.
ISSN:0167-7799
1879-3096
1879-3096
DOI:10.1016/j.tibtech.2014.06.007